Download the 2026 Scientific Program
This program is designed to tackle the most urgent and opportunity‑defining questions, including:
- How to optimize structure–activity relationships, receptor selectivity and signalling bias to maximise efficacy and tolerability
- How to translate amylin biology into meaningful clinical outcomes through forward and reverse translation
- How receptor balance, anti-fibrillation strategies and tissue-specific biology influence therapeutic performance
- How to determine the optimal role of amylin as a monotherapy versus in combination, including where pairing with GLP-1 and other metabolic mechanisms can deliver additive efficacy without compounding tolerability
- How to design and differentiate combination strategies, from receptor balance and dosing to patient selection, sequencing and the clinical positioning of next-generation amylin combinations
Having trouble downloading the brochure? Let us know and we’ll email it to you instead.
Attending Companies Include
